Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Dec 1;3(12):1736-1737.
doi: 10.1001/jamaoncol.2017.1358.

Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial

Olivier Caron  1 , Thierry Frebourg  2   3 , Patrick R Benusiglio  1 , Stéphanie Foulon  4   5 , Laurence Brugières  6
Affiliations
Randomized Controlled Trial

Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial

Olivier Caron et al. JAMA Oncol. .

Abstract

This interim analysis of an ongoing randomized clinical trial presents preliminary findings regarding use of whole-body magnetic resonance imaging for cancer surveillance of TP53 mutation carriers.

Trial registration: ClinicalTrials.gov NCT01464086.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

References

    1. Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat. 2014;35(6):654-662. - PubMed
    1. Bougeard G, Renaux-Petel M, Flaman JM, et al. . Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345-2352. - PubMed
    1. Ruijs MW, Verhoef S, Rookus MA, et al. . TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010;47(6):421-428. - PubMed
    1. Gonzalez KD, Noltner KA, Buzin CH, et al. . Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27(8):1250-1256. - PubMed
    1. Mai PL, Best AF, Peters JA, et al. . Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673-3681. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data